[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359922-105":59,"doc-detail-359922-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","copy-number-amplification-and-c-myc-transcriptional-activation-mediated-rna-binding-protein-mex3a-promotes-egfr-tki-resistance-in-nonsmall-cell-lung-cancer","Copy Number Amplification and c-Myc Transcriptional Activation-Mediated RNA-Binding Protein MEX3A Promotes EGFR-TKI Resistance in Non–Small-Cell Lung Cancer","","Objective focuses on the functional role and activation mechanisms of RNA-binding protein MEX3A in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non–small-cell lung cancer (NSCLC). Methods use paired tumor specimens from 18 advanced NSCLC patients pre-treatment and after TKI resistance, combining CCK-8/colony assays with CNV, qRT-PCR, Western blotting, and ChIP. In vivo xenograft testing evaluates MEX3A knockdown effects on tumor growth and TKI sensitivity. Results show MEX3A upregulation in resistant tissues, correlating with poorer survival and promoting resistance in vitro and in vivo. Mechanistically, copy number amplification activates MEX3A and c-Myc drives transcriptional activation, suggesting a therapeutic target to overcome EGFR-TKI resistance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/copy-number-amplification-and-c-myc-transcriptional-activation-mediated-rna-binding-protein-mex3a-promotes-egfr-tki-resistance-in-nonsmall-cell-lung-cancer/359922/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/copy-number-amplification-and-c-myc-transcriptional-activation-mediated-rna-binding-protein-mex3a-promotes-egfr-tki-resistance-in-nonsmall-cell-lung-cancer/359922.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does this study address about MEX3A in NSCLC?","Question",{"text":113,"@type":114},"It investigates the functional role and the activation mechanisms of the RNA-binding protein MEX3A in acquired resistance to EGFR-TKIs in non–small-cell lung cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were paired patient samples and laboratory assays used to test MEX3A?",{"text":118,"@type":114},"Paired tumor specimens from patients before treatment and after developing TKI resistance were used, with in vitro functional assays (CCK-8 and colony formation) and genomic/transcriptional analyses including CNV analysis, qRT-PCR, Western blotting, and ChIP.",{"name":120,"@type":111,"acceptedAnswer":121},"What mechanism explains how MEX3A becomes activated during TKI resistance?",{"text":122,"@type":114},"Genomic copy number amplification can increase MEX3A activation, while transcriptional regulation by c-Myc can activate MEX3A expression, together promoting EGFR-TKI resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359922,1790211092,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Thoracic Cancer  \nORIGINAL ARTICLE  OPEN ACCESS   \nCopy Number Amplification and c-Myc Transcriptional Activation-Mediated RNA-Binding Protein MEX3A Promotes EGFR-TKI Resistance in Non–Small-Cell Lung Cancer  \nShi Xiling1 | Du Lin1 | Dai Jiali1 | Zhang Chen1  | Huang Ruohan1 | Zhang Chang2 | Guo Renhua1  | Li Jun1  \n1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China | 2Department of Public Health, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China  \nCorrespondence: Zhang Chang ([changzhang2525@163.com](changzhang2525@163.com)) | Guo renhua ([rhguo@njmu.edu.cn](rhguo@njmu.edu.cn)) | Li Jun ([mc_owen@163.com](mc_owen@163.com))  \nReceived: 15 December 2025 | Revised: 17 March 2026 | Accepted: 11 April 2026  \nKeywords: copy number amplification | EGFR-TKI | non–small-cell lung cancerRBP  \nABSTRACT  \nObjective: To investigate the functional role and activation mechanisms of RNA-binding protein MEX3A in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non–small-cell lung cancer (NSCLC) .  \nMethods: Paired tumor specimens were from 18 advanced NSCLC patients with sensitizing EGFR mutations before treatment and after developing TKI resistance. In vitro functional assays, including CCK-8 and colony formation, were conducted to evaluate the impact of MEX3A on EGFR-TKI sensitivity. At the genomic level, copy number variation (CNV) analysis and quantitative real-time PCR (qRT-PCR) validated the genomic relationship between MEX3A copy number and expression. Transcriptional regulation by c-Myc was examined via qRT-PCR, Western blotting, and chromatin immunoprecipitation (ChIP) . Finally, the in vivo effects of MEX3A knockdown on tumor growth and TKI sensitivity were evaluated using a xenograft tumor model.  \nResults: MEX3A was significantly upregulated in TKI-resistant tissues, correlating with poorer survival. MEX3A promoted EGFR-TKI resistance of NSCLC, both in vitro and in vivo. Mechanistically, at the genomic level, copy number amplification can drive the activation of MEX3A, and at the transcriptional level, the transcription factor c-Myc can activate its expression. Conclusion: MEX3A is a key molecule that promotes acquired EGFR-TKI resistance in NSCLC. Its activation is mediated by both genomic copy number amplification and c-Myc-dependent transcriptional regulation, thereby clarifying the activation reasons of MEX3A in TKI resistance at two levels. Our findings suggest that MEX3A may serve as a potential therapeutic target for overcoming TKI resistance in NSCLC.  \n1 | Introduction  \nLung cancer represents one of the most prevalent and lethal malignancies globally, with persistently high incidence and mortality rates [1]. It is classified into two primary histological types: non–small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) [2] . NSCLC accounts for approximately 85% of  \ncases, making it the predominant form [3] . Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective targeted therapies for treating EGFR-sensitive mutation NSCLC [4] . Currently, EGFR-TKIs, represented by drugs such as gefitinib and osimertinib, are widely used in first-line treatment for patients with EGFR-sensitive mutations, significantly extending survival and improving the quality of life  \n\n| Shi Xiling, Du Lin, Dai Jiali and Zhang Chen contributed and equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2026 The Author(s) . Thoracic Cancer published by John Wiley & Sons Australia, Ltd. |\n\nThoracic Cancer, 2026; 17:e70284 1 of 10  \n[https://doi.org/10.1111/1759-7714.70284](https://doi.org/10.1111/1759-7","cbCaikOeHabuaox4","https://ap.wps.com/l/cbCaikOeHabuaox4","pdf",4554476,"English","# Introduction\n## Background on lung cancer and EGFR-TKI resistance\n## RNA-binding proteins and drug resistance\n## Rationale for studying MEX3A","[{\"question\":\"What question does this study address about MEX3A in NSCLC?\",\"answer\":\"It investigates the functional role and the activation mechanisms of the RNA-binding protein MEX3A in acquired resistance to EGFR-TKIs in non–small-cell lung cancer.\"},{\"question\":\"How were paired patient samples and laboratory assays used to test MEX3A?\",\"answer\":\"Paired tumor specimens from patients before treatment and after developing TKI resistance were used, with in vitro functional assays (CCK-8 and colony formation) and genomic/transcriptional analyses including CNV analysis, qRT-PCR, Western blotting, and ChIP.\"},{\"question\":\"What mechanism explains how MEX3A becomes activated during TKI resistance?\",\"answer\":\"Genomic copy number amplification can increase MEX3A activation, while transcriptional regulation by c-Myc can activate MEX3A expression, together promoting EGFR-TKI resistance.\"}]","Copy Number Amplification and c-Myc Transcriptional Activation-Mediated RNA-Binding Protein MEX3A Promotes EGFR-TKI Resistance in Non–Small-Cell Lung Cancer | PDF",1790138210,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02332e4a5b81fc72d57a10c6e3842960.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/834f27b42364f23014f5263172859c3e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0289ba18005ff1e8856cd6ce2db87859.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db1c70d9fd7906ea93437c435cd00766.webp",980,1287]